News from Helsinn A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 01, 2016, 14:04 ET Helsinn Integrative Care anuncia la aprobación de Xonrid® Gel por la 510(K) FDA

Helsinn Integrative Care, la unidad empresarial de Helsinn centrada en productos de cuidados paliativos para el cáncer no farmacéuticos y basados...


Dec 01, 2016, 11:23 ET Helsinn Integrative Care annonce avoir obtenu de la FDA une autorisation 510(K) de mise sur le marché pour son gel Xonrid® classé dispositif médical

Helsinn Integrative Care, unité commerciale d'Helsinn spécialisée dans les produits non pharmaceutiques de soins de support en oncologie fondés...


Dec 01, 2016, 11:22 ET Helsinn Integrative Care gibt 510(K)-Freigabe der FDA für Medizinprodukt Xonrid®-Gel bekannt

Helsinn Integrative Care, Helsinns Geschäftszweig, der sich auf evidenzbasierte, nicht-pharmazeutische Pflegeprodukte für Krebs konzentriert, gibt...


Dec 01, 2016, 03:00 ET Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid® Gel

Helsinn Integrative Care, Helsinn's business unit focused on evidence-based, non-pharmaceutical cancer supportive care products, today announces...


Jun 01, 2016, 09:00 ET Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer (NSCLC)

Pooled, Post-hoc Efficacy Data Analysis From the ROMANA 1 and ROMANA 2 Phase III Studies Demonstrates That in NSCLC Patients With Cachexia and a...


May 05, 2016, 06:53 ET Helsinn apoya la Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award en cuidados de apoyo al cáncer

- Helsinn apoya la Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award en cuidados de apoyo al cáncer con el apoyo...


May 04, 2016, 14:04 ET Helsinn Announces Top-Line Results of its Phase IIb Trial With Elsiglutide for the Prevention of Chemotherapy-induced Diarrhea in Colorectal Cancer Patients

- In the Trial, Elsiglutide Reduced the Incidence of Chemotherapy-induced Diarrhea in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy...


May 03, 2016, 11:05 ET Helsinn soutient la Conquer Cancer Foundation/le prix Anna Braglia Young Investigator Award dans le domaine des soins de support en oncologie en finançant les travaux de recherche de jeunes médecins prometteurs

Helsinn annonce un financement annuel destiné à aider de jeunes et brillants médecins à exploiter leur potentiel...


May 03, 2016, 07:40 ET Helsinn unterstützt Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award im Bereich Krebsfürsorge durch finanzielle Forschungshilfen für vielversprechende junge Mediziner

Helsinn gibt jährliche finanzielle Zuwendung bekannt, um talentierte junge Medizinern dabei zu unterstützen, ihr volles Potenzial zu...


May 03, 2016, 03:00 ET Helsinn Supports the Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care With Research Funding Support For Promising Young Physicians

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to announce that it will honor the life of Anna...


Apr 11, 2016, 06:00 ET Helsinn Supports the Development of NCCN Guidelines for Patients® on Nausea and Vomiting, with a Sponsorship Grant

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, announces that it is supporting the NCCN Foundation® in the...


Mar 24, 2016, 04:30 ET Helsinn Advanced Synthesis SA Wins 2016 CMO Leadership Awards

Helsinn wins in five categories; Quality, Reliability, Capabilities, Expertise and Compatibility, earning a place among the best in the industry,...


Mar 23, 2016, 04:00 ET Helsinn Presents Quality of Life, Its First Group Sustainability Report

Helsinn Group is pleased to present its first group sustainability report, Quality of Life, demonstrating that being a good corporate citizen is...


Feb 23, 2016, 03:00 ET Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology

- Pivotal data from anamorelin ROMANA 1 and ROMANA 2 Phase III studies published in world-leading, peer-reviewed medical journal  - Study...


Feb 16, 2016, 04:00 ET Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of Anamorelin in Northern Europe Countries

This exclusive agreement strengthens previous alliances with Mundipharma and its network of independent associated companies in cancer...


Dec 15, 2015, 01:15 ET Swissmedic Approves Akynzeo® (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Switzerland

  - First Fixed Combination Targeting Two Key Pathways Involved in CINV -  Helsinn, the Swiss Group focused on building quality...


Nov 30, 2015, 03:00 ET Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency (EMA) accepted...


Oct 13, 2015, 03:00 ET Helsinn Reaches Settlement Agreement Regarding Patent Dispute on ALOXI®

Helsinn Healthcare SA announces that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. to resolve certain patent...


Sep 29, 2015, 03:00 ET Helsinn Group Awarded Global CEO Cancer Gold Standard Accreditation

The prestigious accreditation recognizes Helsinn's commitment to reducing cancer risk through the promotion of healthier lifestyle, earlier...


Oct 30, 2014, 03:00 ET New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue and improve health-related...


Jan 09, 2001, 00:00 ET New Investments Reinforce Helsinn's Chemical Business

BIASCA, Switzerland, Jan. 9 /PRNewswire/ -- The recent completion of Helsinn Advanced Synthesis SA, a state-of-the-art facility dedicated to the...